In female ICR mice with K562-associated bone pain, intraperitoneal Lappaconite significantly reduced spontaneous pain compared with the untreated K562 group, without completely alleviating it. Lappaconite also restored inclined plate balance that had declined in the K562 cells transplanted group. In outbred male rats with aconitine-induced arrhythmia, intravenous Lappaconite administered before aconitine showed an antiarrhythmic effect in comparison with control. [2,3]
Spontaneous pain reduction in a mouse bone pain model
Animal study · female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20) [2]
Female ICR mice with K562-associated bone pain received intraperitoneal Lappaconite. Treatment significantly reduced spontaneous pain compared with the untreated K562 group but did not completely alleviate pain.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injection
- Treatment course
- on day 15, day 17, and day 19 after cancer cell transplantation
- Lappaconite 4 mg/kg
- Model: female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Lappaconite; Compound label in the paper: Lappaconitine
The paper names Lappaconite without stating the salt or form; not verified as the hydrobromide form supplied as A10515. No dose conversion or lot validation.
Materials and Methods > Animal model (S3, S4, S7, S8); Materials and Methods > Lappaconitine treatment (S10); Materials and Methods > Pain behavior scoring (S11); Results > Pain behavior scoring (S44)
spontaneous pain scoring: spontaneous pain scoring; comparator: untreated K562 group — Materials and Methods > Pain behavior scoring (S11); Results > Pain behavior scoring (S44)
Lappaconite 4 mg/kg · Materials and Methods > Lappaconitine treatment (S10); Results > Pain behavior scoring (S44)
Antiarrhythmic effect in an aconitine rat model
Animal study · outbred male rats; aconitine model of arrhythmia [3]
Outbred male rats received intravenous Lappaconite before aconitine administration in an arrhythmia model. An antiarrhythmic effect was reported in comparison with control.
Conditions shared by the study groups
- Route
- intravenously
- Treatment course
- 5 min before the administration of the aconitine solution
- Lappaconite 0.05 mg/kg
- Model: outbred male rats; aconitine model of arrhythmia
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Lappaconite; Compound label in the paper: Allapinin
The paper names Lappaconite without stating the salt or form; not verified as the hydrobromide form supplied as A10515. No dose conversion or lot validation.
Material and Methods > Antiarrhythmic activity study (S98, S99, S101, S103); Table 4 (T4.h1, T4.h2, T4.r1, T4.r15)
Antiarrhythmic effect (%): Antiarrhythmic effect (%); comparator: H2O, 0.2 mL — Material and Methods > Antiarrhythmic activity study (S103); Table 4 (T4.h2, T4.r15)
Lappaconite 0.05 mg/kg · Material and Methods > Antiarrhythmic activity study (S103); Table 4 (T4.h2, T4.r15)
Inclined Plate Balance in a Mouse Bone Pain Model
Animal study · female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20) [2]
Female ICR mice in a bone pain model received Lappaconite by intraperitoneal injection. Treatment restored inclined plate balance that had been markedly reduced in the K562 cells transplanted group.
Conditions shared by the study groups
- Route
- intraperitoneal (i.p.) injection
- Treatment course
- on day 15, day 17, and day 19 after cancer cell transplantation
- Lappaconite 4 mg/kg
- Model: female ICR mouse; bone pain with lappaconitine treatment group (K562 cells+lappaconitine group) (n = 20)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Lappaconite; Compound label in the paper: Lappaconitine
The paper names Lappaconite without stating the salt or form; not verified as the hydrobromide form supplied as A10515. No dose conversion or lot validation.
Materials and Methods > Animal model (S3, S4, S7, S8); Materials and Methods > Lappaconitine treatment (S10); Materials and Methods > Pain behavior scoring (S19); Results > Pain behavior scoring (S46)
The loss-balance degree for the inclined plate: The loss-balance degree for the inclined plate; comparator: K562 cells transplanted group — Materials and Methods > Pain behavior scoring (S19); Results > Pain behavior scoring (S46)
Lappaconite 4 mg/kg · Materials and Methods > Lappaconitine treatment (S10); Results > Pain behavior scoring (S46)